Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15939MR)

This product GTTS-WQ15939MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Felinized
RefSeq XM_004001117.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100144611
UniProt ID A0A337SBN0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15939MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11083MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ13466MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ11486MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ7000MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ15542MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ5759MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ6457MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ7116MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999302
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW